March 10, 2021
Fortis Life Sciences, a life sciences company offering products and solutions for the life sciences industry, has acquired the premium antibody company Bethyl Laboratories. Based in Montgomery, Texas, Bethyl Laboratories has a long history of offering the highest quality primary and secondary antibodies to its customers, as well as other protein detection reagents. Bethyl Laboratories is well known for industry leading performance and the highest standards in antibody validation, and prior to the acquisition by Fortis, had successfully operated as a private, family-owned, and operated business for nearly 50 years.
"Bethyl Laboratories is an ideal business to bring onto the Fortis Life Sciences platform," said Brian Kim, CEO of Fortis. "Bethyl enjoys a sterling quality reputation with its customers and industry peers. Bethyl’s high quality, proprietary products are exclusively developed, validated, and manufactured at their animal farm and manufacturing site in Montgomery, Texas. We could not be more pleased with the acquisition of Bethyl as a starting point for Fortis. We are honored to work with John Carwile, the CEO of Bethyl and his management team."
Bethyl CEO, John Carwile, MD has been leading the organization for the past 10 years. He is the successor to Henry Carwile, DVM, who founded the Company with his wife Sally. John and the Carwile family have seen tremendous success with strong market adoption and positive perception of their world class antibodies. Commenting on plans for Bethyl’s future, John stated, "We are excited to partner with Fortis Life Sciences and to launch Bethyl Laboratories to the next stage of growth. We believe with the strong differentiation of our product lines and Fortis’s experience in scaling businesses, we will be able to reach our ambitious vision for the company. I look forward to leading the growth of the antibodies and protein business within the Fortis family."
The transaction closed in November 2020.